Citation Impact
Citing Papers
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
2017 Standout
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
2009 Standout
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Complete Genetic Correction of iPS Cells From Duchenne Muscular Dystrophy
2009 StandoutNobel
Multiple myeloma
2014
Proteasome inhibitors in cancer therapy
2017
Acute kidney injury
2012 Standout
Ferroptosis: Death by Lipid Peroxidation
2015 Standout
Neutrophils at work
2014 Standout
Regulation and Functions of the ER-Associated Nrf1 Transcription Factor
2022 StandoutNobel
Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells
2009 Nature
Kidney transplantation across HLA and ABO antibody barriers
2013
Dynamic changes in cellular and microenvironmental composition can be controlled to elicit in vitro human hematopoietic stem cell expansion
2005
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
2014
Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases
2014 Standout
Metabolic Regulation of Hematopoietic Stem Cells in the Hypoxic Niche
2011 StandoutNobel
The Use of Induced Pluripotent Stem Cells in Drug Development
2011 StandoutNobel
Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
2017
Macrophages in immunoregulation and therapeutics
2023 Standout
Rhabdomyolysis and Acute Kidney Injury
2009 Standout
Acute Kidney Injury in Patients with Cancer
2017
Recent updates on CAR T clinical trials for multiple myeloma
2019
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Acute kidney injury
2019 Standout
Acquisition of G0 state by CD34-positive cord blood cells after bone marrow transplantation
2010
Pyroptosis: mechanisms and diseases
2021 Standout
Aging of the innate immune system
2010
Transfusion reactions: prevention, diagnosis, and treatment
2016
Induced pluripotent stem cells and reprogramming: seeing the science through the hype
2009 StandoutNobel
How were new medicines discovered?
2011 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
2019
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
2013
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Eicosanoids and cancer
2010 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
CAR-T cell therapy: current limitations and potential strategies
2021 Standout
An Immunosuppressive Antibody–Drug Conjugate
2015
The Hallmarks of Aging
2013 Standout
Neutrophils as a Therapeutic Target in Cancer
2019
Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney
2011
Age Sensitivity of NFκB Abundance and Programmed Cell Death in Erythrocytes Induced by NFκB Inhibitors
2013 Standout
Light chain deposition disease: novel biological insights and treatment advances
2012
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
2021
Neutrophil recruitment and function in health and inflammation
2013 Standout
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
2016 Standout
Mechanisms and pathophysiological significance of eryptosis, the suicidal erythrocyte death
2015 Standout
Donor HLA-specific Abs: to BMT or not to BMT?
2015
Rituximab-Associated Infections
2010
Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology
2016
Monoclonal antibodies in myeloma.
2015
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
2022 StandoutNobel
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
2016 Standout
Desensitization in kidney transplantation: review and future perspectives
2014
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
2020
Aging, Cellular Senescence, and Cancer
2012 Standout
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity
2017 StandoutNobel
2016 US lymphoid malignancy statistics by World Health Organization subtypes
2016 Standout
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
2006 StandoutNature
Activation of hypoxia-inducible factor-1α (Hif-1α) delays inflammation resolution by reducing neutrophil apoptosis and reverse migration in a zebrafish inflammation model
2011
Desensitization for solid organ and hematopoietic stem cell transplantation
2014
Neue Ziele für die Photopharmakologie
2016 StandoutNobel
Molecular and Secretory Profiles of Human Mesenchymal Stromal Cells and Their Abilities to Maintain Primitive Hematopoietic Progenitors
2007
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
2018
Recent Stem Cell Advances: Induced Pluripotent Stem Cells for Disease Modeling and Stem Cell–Based Regeneration
2010 StandoutNobel
Resistance to proteasome inhibitors and other targeted therapies in myeloma
2018
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
2013
Disease Tolerance as a Defense Strategy
2012 StandoutScience
Myeloma today: Disease definitions and treatment advances
2015
Paraprotein–Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy
2016
Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.
2012
Non‑covalent proteasome inhibitor PI‑1840 induces apoptosis and autophagy in osteosarcoma cells
2019
Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells
2010 StandoutNobel
Participation of leukotriene C(4) in the regulation of suicidal erythrocyte death.
2009
The CysLT1 Ligand Leukotriene D4 Supports α4β1- and α5β1-Mediated Adhesion and Proliferation of CD34+ Hematopoietic Progenitor Cells
2009
Emerging Targets in Photopharmacology
2016 StandoutNobel
2015
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
2019
Works of Katja Weisel being referenced
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
2016
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
2017
Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide
2008
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
2018
The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-“negative” grade 1/2 follicular lymphomas
2013
DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
2009
Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury
2011
Proteasome inhibition by bortezomib: Effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation
2012
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
2020
European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial
2008
Paraneoplastic granulocyte colony-stimulating factor secretion in soft tissue sarcoma mimicking myeloproliferative neoplasia: a case report
2014
Stromal cell lines from the aorta-gonado-mesonephros region are potent supporters of murine and human hematopoiesis
2006
Regulation of FLT3 and its ligand in normal hematopoietic progenitor cells
2008
Differential Effects of G Protein–Coupled Receptors on Hematopoietic Progenitor Cell Growth Depend on their Signaling Capacities
2007
Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study
2012
OP9 Stroma Augments Survival of Hematopoietic Precursors and Progenitors During Hematopoietic Differentiation from Human Embryonic Stem Cells
2008
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
2018
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS
2018
Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.
2015
Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO ‐incompatible red blood cell transfusion
2014
Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma.
2006
A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM).
2015
Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication
2004
Modulation of CXC Chemokine Receptor Expression and Function in Human Neutrophils during Aging In Vitro Suggests a Role in Their Clearance from Circulation
2009